Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer

Olivér Pintér, J. Molnár, Csaba Tóth, Zoltán Szabó, Joseph Lipták, Pál Fél, György Papp, Endre Hollman, Lajos Hazay, Béla Streit, László Kisbenedek, Miklós Fehér, István Kocsis, László Pajor

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Androgen ablation is palliative and does not cure advanced prostate cancer. The hormone-sensitive cells die and the hormone-resistant cells overgrow, resulting in disease progression. The drug of choice for secondary treatment is estramustine (Estracyt). The success of the therapy is followed by changes of the prostate-specific antigen level and Karnofsky scale. In the present study, the results of estramustine treatment of 79 patients with advanced prostate cancer in 12 hospitals were evaluated. The mean prostate-specific antigen level improved for 6 months, but rose from the ninth month on. The improvement in the subjective condition of the patients paralleled the change in the prostate-specific antigen level. The short time of improvement was a consequence of the very high prostate-specific antigen level and the poor general condition. Estramustine administration is recommended when the prostate-specific antigen level becomes more than doubled following primary treatment. At a starting prostate-specific antigen level of > 100 ng/ml, the treatment leads to total androgen blockade. If the prostate-specific antigen level has not decreased after treatment for 3 months, the secondary strategy is to apply chemotherapy.

Original languageEnglish
Pages (from-to)787-792
Number of pages6
JournalIn Vivo
Volume19
Issue number4
Publication statusPublished - Jul 2005

Fingerprint

Estramustine
Karnofsky Performance Status
Prostate-Specific Antigen
Prostatic Neoplasms
Therapeutics
Androgens
Hormones
Chemotherapy
Ablation
Disease Progression
Drug Therapy

Keywords

  • Advanced prostate cancer
  • Estracyt/estramustine
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer. / Pintér, Olivér; Molnár, J.; Tóth, Csaba; Szabó, Zoltán; Lipták, Joseph; Fél, Pál; Papp, György; Hollman, Endre; Hazay, Lajos; Streit, Béla; Kisbenedek, László; Fehér, Miklós; Kocsis, István; Pajor, László.

In: In Vivo, Vol. 19, No. 4, 07.2005, p. 787-792.

Research output: Contribution to journalArticle

Pintér, O, Molnár, J, Tóth, C, Szabó, Z, Lipták, J, Fél, P, Papp, G, Hollman, E, Hazay, L, Streit, B, Kisbenedek, L, Fehér, M, Kocsis, I & Pajor, L 2005, 'Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer', In Vivo, vol. 19, no. 4, pp. 787-792.
Pintér, Olivér ; Molnár, J. ; Tóth, Csaba ; Szabó, Zoltán ; Lipták, Joseph ; Fél, Pál ; Papp, György ; Hollman, Endre ; Hazay, Lajos ; Streit, Béla ; Kisbenedek, László ; Fehér, Miklós ; Kocsis, István ; Pajor, László. / Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer. In: In Vivo. 2005 ; Vol. 19, No. 4. pp. 787-792.
@article{7787ee863992470887cc14c333faf30d,
title = "Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer",
abstract = "Androgen ablation is palliative and does not cure advanced prostate cancer. The hormone-sensitive cells die and the hormone-resistant cells overgrow, resulting in disease progression. The drug of choice for secondary treatment is estramustine (Estracyt). The success of the therapy is followed by changes of the prostate-specific antigen level and Karnofsky scale. In the present study, the results of estramustine treatment of 79 patients with advanced prostate cancer in 12 hospitals were evaluated. The mean prostate-specific antigen level improved for 6 months, but rose from the ninth month on. The improvement in the subjective condition of the patients paralleled the change in the prostate-specific antigen level. The short time of improvement was a consequence of the very high prostate-specific antigen level and the poor general condition. Estramustine administration is recommended when the prostate-specific antigen level becomes more than doubled following primary treatment. At a starting prostate-specific antigen level of > 100 ng/ml, the treatment leads to total androgen blockade. If the prostate-specific antigen level has not decreased after treatment for 3 months, the secondary strategy is to apply chemotherapy.",
keywords = "Advanced prostate cancer, Estracyt/estramustine, Prostate-specific antigen",
author = "Oliv{\'e}r Pint{\'e}r and J. Moln{\'a}r and Csaba T{\'o}th and Zolt{\'a}n Szab{\'o} and Joseph Lipt{\'a}k and P{\'a}l F{\'e}l and Gy{\"o}rgy Papp and Endre Hollman and Lajos Hazay and B{\'e}la Streit and L{\'a}szl{\'o} Kisbenedek and Mikl{\'o}s Feh{\'e}r and Istv{\'a}n Kocsis and L{\'a}szl{\'o} Pajor",
year = "2005",
month = "7",
language = "English",
volume = "19",
pages = "787--792",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer

AU - Pintér, Olivér

AU - Molnár, J.

AU - Tóth, Csaba

AU - Szabó, Zoltán

AU - Lipták, Joseph

AU - Fél, Pál

AU - Papp, György

AU - Hollman, Endre

AU - Hazay, Lajos

AU - Streit, Béla

AU - Kisbenedek, László

AU - Fehér, Miklós

AU - Kocsis, István

AU - Pajor, László

PY - 2005/7

Y1 - 2005/7

N2 - Androgen ablation is palliative and does not cure advanced prostate cancer. The hormone-sensitive cells die and the hormone-resistant cells overgrow, resulting in disease progression. The drug of choice for secondary treatment is estramustine (Estracyt). The success of the therapy is followed by changes of the prostate-specific antigen level and Karnofsky scale. In the present study, the results of estramustine treatment of 79 patients with advanced prostate cancer in 12 hospitals were evaluated. The mean prostate-specific antigen level improved for 6 months, but rose from the ninth month on. The improvement in the subjective condition of the patients paralleled the change in the prostate-specific antigen level. The short time of improvement was a consequence of the very high prostate-specific antigen level and the poor general condition. Estramustine administration is recommended when the prostate-specific antigen level becomes more than doubled following primary treatment. At a starting prostate-specific antigen level of > 100 ng/ml, the treatment leads to total androgen blockade. If the prostate-specific antigen level has not decreased after treatment for 3 months, the secondary strategy is to apply chemotherapy.

AB - Androgen ablation is palliative and does not cure advanced prostate cancer. The hormone-sensitive cells die and the hormone-resistant cells overgrow, resulting in disease progression. The drug of choice for secondary treatment is estramustine (Estracyt). The success of the therapy is followed by changes of the prostate-specific antigen level and Karnofsky scale. In the present study, the results of estramustine treatment of 79 patients with advanced prostate cancer in 12 hospitals were evaluated. The mean prostate-specific antigen level improved for 6 months, but rose from the ninth month on. The improvement in the subjective condition of the patients paralleled the change in the prostate-specific antigen level. The short time of improvement was a consequence of the very high prostate-specific antigen level and the poor general condition. Estramustine administration is recommended when the prostate-specific antigen level becomes more than doubled following primary treatment. At a starting prostate-specific antigen level of > 100 ng/ml, the treatment leads to total androgen blockade. If the prostate-specific antigen level has not decreased after treatment for 3 months, the secondary strategy is to apply chemotherapy.

KW - Advanced prostate cancer

KW - Estracyt/estramustine

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=21344460530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344460530&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 787

EP - 792

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 4

ER -